1 Kissebah, AH & Krakower, GR (1994) Regional adiposity and morbidity. Physiol Rev 74, 761–811.
2 Formiguera, X & Canton, A (2004) Obesity: epidemiology and clinical aspects. Best Pract Res Clin Gastroenterol 18, 1125–1146.
3 Hjelkrem, MC, Torres, DM & Harrison, SA (2008) Nonalcoholic fatty liver disease. Minerva Med 99, 583–593.
4 Harrison, SA & Diehl, AM (2002) Fat and the liver – a molecular overview. Semin Gastrointest Dis 13, 3–16.
5 Youssef, W & McCullough, AJ (2002) Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis 13, 17–30.
6 Fong, DG, Nehra, V, Lindor, KD, et al. (2000) Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 32, 3–10.
7 Reid, AE (2001) Nonalcoholic steatohepatitis. Gastroenterology 121, 710–723.
8 Angulo, P (2005) Nonalcoholic fatty liver disease. Rev Gastroenterol Mex 70, 52–56.
9 Clark, JM, Brancati, FL & Diehl, AM (2002) Nonalcoholic fatty liver disease. Gastroenterology 122, 1649–1657.
10 Angulo, P (2007) GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 25, 883–889.
11 Day, CP (2002) Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 16, 663–678.
12 Gary-Bobo, M, Elachouri, G, Gallas, JF, et al. (2007) Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46, 122–129.
13 Nagao, K, Inoue, N, Wang, YM, et al. (2005) Dietary conjugated linoleic acid alleviates nonalcoholic fatty liver disease in Zucker (fa/fa) rats. J Nutr 135, 9–13.
14 Shirouchi, B, Nagao, K, Inoue, N, et al. (2008) Dietary phosphatidylinositol prevents the development of nonalcoholic fatty liver disease in Zucker (fa/fa) rats. J Agric Food Chem 56, 2375–2379.
15 Nagao, K & Yanagita, T (2008) Bioactive lipids in metabolic syndrome. Prog Lipid Res 47, 127–146.
16 Chang, R (1996) Functional properties of edible mushrooms. Nutr Rev 54, S91–S93.
17 Wasser, SP (2002) Medical mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 60, 258–274.
18 Ukawa, Y, Furuichi, Y, Kokean, Y, et al. (2002) Effect of hatakeshimeji (Lyophyllum decastes Sing.) mushroom on serum lipid levels in rats. J Nutr Sci Vitaminol 8, 73–76.
19 Zaidman, BZ, Yassin, M, Mahajna, J, et al. (2005) Medical mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol 67, 453–468.
20 Watanabe, A, Kobayashi, M, Hayashi, S, et al. (2006) Protection against d-galactosamine-induced acute liver injury by oral administration of extracts from Lentinus edodes mycelia. Biol Pharm Bull 29, 1651–1654.
21 Ukawa, Y, Izumi, Y, Ohbuchi, T, et al. (2007) Oral administration of the extract from Hatakeshimeji (Lyophyllum decastes Sing.) mushroom inhibits the development of atopic dermatitis-like skin lesions in NC/Nga mice. J Nutr Sci Vitaminol 53, 293–296.
22 Nagamori, N (2007) Simple equipment cultivation of Panellus serotinus. Kyushu J Forrest Res 60, 146–148.
23 Nagao, K, Inoue, N, Inafuku, M, et al. (2010) Mukitake mushroom (Panellus serotinus) alleviates nonalcoholic fatty liver disease through the suppression of monocyte chemoattractant protein 1 production in db/db mice. J Nutr Biochem 21, 418–423.
24 Folch, J, Lees, M & Sloane Stanley, GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226, 497–509.
25 Fletcher, MJ (1968) A colorimetric method for estimating serum triglycerides. Clin Chim Acta 22, 393–397.
26 Sperry, WM & Webb, M (1950) A revision of the Schoenheimer–Sperry method for cholesterol determination. J Biol Chem 187, 97–106.
27 Ochoa, S (1955) Malic enzyme: malic enzymes from pigeon and wheat germ. Methods Enzymol 1, 323–326.
28 Kelley, DS & Kletzien, RF (1984) Ethanol modulation of the hormonal and nutritional regulation of glucose 6-phosphate dehydrogenase activity in primary cultures of rat hepatocytes. Biochem J 217, 543–549.
29 Kelley, DS, Nelson, GJ & Hunt, JE (1986) Effect of prior nutritional status on the activity of lipogenic enzymes in primary monolayer cultures of rat hepatocytes. Biochem J 235, 87–90.
30 Hummel, KP, Dickie, MM & Coleman, DL (1966) Diabetes, a new mutation in the mouse. Science 153, 1127–1128.
31 Chen, H, Charlat, O, Tartaglia, LA, et al. (1996) Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84, 491–495.
32 Lee, GH, Proenca, R, Montez, JM, et al. (1996) Abnormal splicing of the leptin receptor in diabetic mice. Nature 379, 632–635.
33 Marceau, P, Biron, S, Hould, FS, et al. (1999) Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 84, 1513–1517.
34 Marchesini, G, Brizi, M, Bianchi, G, et al. (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50, 1844–1850.
35 Marchesini, G, Bugianesi, E, Forlani, G, et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37, 917–923.
36 Hotamisligil, GS (1999) The role of TNF α and TNF receptors in obesity and insulin resistance. J Intern Med 245, 621–625.
37 Cave, M, Deaciuc, I, Mendez, C, et al. (2007) Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem 18, 184–195.
38 Baggiolini, M (1998) Chemokines and leukocyte traffic. Nature 392, 565–568.
39 Sartipy, P & Loskutoff, DJ (2003) Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 100, 7265–7270.
40 Kanda, H, Tateya, S, Tamori, Y, et al. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116, 1494–1505.
41 Maeda, N, Shimomura, I, Kishida, K, et al. (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8, 731–737.
42 Karin, M & Delhase, M (2000) The IκB kinase (IKK) and NF-κB: key elements of proinflammatory signalling. Semin Immunol 12, 85–98.
43 Ghosh, S & Karin, M (2002) Missing pieces in the NF-κB puzzle. Cell 109, S81–S96.
44 Kim, JK, Kim, YJ, Fillmore, JJ, et al. (2001) Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 108, 437–446.
45 Grundy, SM (2004) Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 89, 2595–2600.
46 Matsuzawa, Y (2005) Adipocectin: identification, physiology and clinical relevance in metabolic and vascular disease. Nat Clin Pract Cardiovasc Med 6, 7–14.
47 Xu, A, Wang, Y, Keshaw, H, et al. (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver disease in mice. J Clin Invest 112, 91–100.
48 Lopez-Bermejo, A, Botas, P, Funahashi, T, et al. (2004) Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol 60, 256–253.
49 Bajaj, M, Suraamornkul, S, Piper, P, et al. (2004) Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type2 diabetes patients. J Clin Endocrinol Metab 89, 200–206.